Management of Atrial Fibrillation in Patients with Controlled Heart Rate and Low Diastolic Blood Pressure

Anticoagulation Decision‑Making

Calculate the CHA₂DS₂‑VASc score and initiate oral anticoagulation when the score is ≥ 2 in men (or ≥ 3 in women). The score assigns points for congestive heart failure, hypertension, diabetes, prior stroke/TIA, and vascular disease. [European Society of Cardiology] [3] [American College of Cardiology] [1]
Direct oral anticoagulants (DOACs) are preferred over warfarin for non‑valvular atrial fibrillation because they provide lower bleeding risk and superior efficacy. [American College of Cardiology] [1]
Warfarin remains the anticoagulant of choice for patients with rheumatic heart disease or mechanical heart valves, targeting an INR of 2.0–3.0. [American College of Cardiology] [4]

No additional rate‑control medication is required because the resting heart rate of 64 bpm is already below the lenient target of < 110 bpm. [American College of Cardiology] [5]
A diastolic blood pressure of 48 mmHg contraindicates initiation or escalation of AV‑nodal‑blocking agents (β‑blockers, non‑DHP calcium‑channel blockers, digoxin) due to the risk of further hypotension, excessive bradycardia, and syncope. [American College of Cardiology] [5]
If the patient is already receiving any rate‑control drug, dose reduction or discontinuation should be considered given the low diastolic pressure and adequate heart‑rate control. [European Society of Cardiology] [6]

Screen for reversible precipitants of atrial fibrillation—including thyroid function, serum electrolytes, and renal function—using appropriate laboratory tests. [American College of Cardiology] [1]
Perform a transthoracic echocardiogram to assess structural heart disease, valvular abnormalities, and left‑ventricular function. [European Society of Cardiology] [6]
Investigate the low diastolic pressure for possible aortic regurgitation, severe anemia, thyrotoxicosis, medication effects, or volume depletion. [European Society of Cardiology] [2] [European Society of Cardiology] [3]

Amiodarone is the preferred anti‑arrhythmic for rhythm control in this setting because it exerts minimal myocardial depression and has a low pro‑arrhythmic potential. [American Heart Association] [7]
Recommended amiodarone loading: 600 mg daily for 4 weeks (or 1 g daily for 1 week) followed by standard maintenance dosing. [American Heart Association] [7]
Class IC agents (flecainide, propafenone) and sotalol should be avoided because adequate rate‑control backup cannot be safely achieved and they may cause hypotension. [American Heart Association] [7]

Arrange outpatient review within 1–2 weeks to confirm anticoagulation initiation, reassess blood pressure and heart rate, review laboratory results, and evaluate symptom burden using the EHRA symptom score. [European Society of Cardiology] [6]
If warfarin is used, monitor INR to maintain the target range of 2.0–3.0; if a DOAC is used, perform periodic renal‑function monitoring, especially for dabigatran and edoxaban. [American College of Cardiology] [1]
Obtain a 12‑lead ECG at follow‑up to detect:
- QT‑interval prolongation when on amiodarone, sotalol, or dofetilide [American Heart Association] [7]
- QRS widening when on flecainide or propafenone [American College of Cardiology] [5]
- PR‑interval prolongation with any anti‑arrhythmic [American Heart Association] [7]
If the patient develops symptoms of hypoperfusion (dizziness, presyncope, fatigue, confusion), urgent evaluation is required to rule out tachycardia‑induced cardiomyopathy, severe valvular disease, or left‑ventricular dysfunction. [American College of Cardiology] [5]

All facts are presented in English, with patient‑specific details replaced by generic descriptors.